Search
Research
In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruziCompared the in vitro susceptibility of two strains of Trypanosoma copemani and one strain of T. cruzi against drugs that show trypanocidal activity
Research
Structure-function relationships of the neisserial EptA enzyme responsible for phosphoethanolamine decoration of lipid A: Rationale for drug targetingThis review concentrates on the phosphoethanolamine decoration of lipid A in the pathogenic species of the genus Neisseria
Research
Optimization is required when using linked hospital and laboratory data to investigate respiratory infectionsDespite a recommendation for microbiological testing, only 45% of children hospitalized for respiratory infections in our previous data linkage study linked...
Research
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in childrenOur study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.
Research
Host genetic factors in American cutaneous leishmaniasis: A critical appraisal of studies conducted in an endemic area of BrazilThis paper reviews American cutaneous leishmaniasis (ACL) immunogenetics in the state of Bahia (BA), northeastern Brazil, highlighting the interacting roles...
Research
Home oxygen therapy for infants and young children with acute bronchiolitis and other lower respiratory tract infections: The HiTHOx programRecent studies have demonstrated that some children with acute bronchiolitis can be successfully managed using home oxygen therapy.
Research
Can linked emergency department data help assess the out-of-hospital burden of acute lower respiratory infectionsThere is a lack of data on the out-of-hospital burden of acute lower respiratory infections (ALRI) in developed countries.
Research
The future of acute rheumatic fever and rheumatic heart disease in AustraliaGlobally, ARF and RHD cause more than a quarter of a million deaths and substantial disability each year.
Research
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 monthsA bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...
Research
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...